3013543-64-8
Chemical Structure
Zovaglutide
Synonym(s): ZT002
- CAS No.: 3013543-64-8
- Formula:C374H584N96O123
- Molecular Weight:8393.21
SMILES: O=C([C@@H](N)CC1=CNC=N1)NC(C)(C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(NCC(NCC(N[C@H](C(N[C@H](C(N2[C@H](C(NCC(N[C@H](C(N[C@H](C(N3[C@H](C(NCC(N[C@H](C(N[C@H](C(N4[C@H](C(NCC(N[C@H](C(N[C@H](C(N5[C@H](C(NCC(N[C@H](C(N[C@H](C(N6[C@H](C(NCC(N[C@H](C(N[C@H](C(N7[C@H](C(NCC(N[C@H](C(N[C@H](C(N8[C@H](C(NCC(N[C@H](C(N[C@H](C(N9[C@H](C(NCC(N[C@H](C(N[C@H](C(N%10[C@H](C(NCC(N[C@H](C(N[C@H](C(N%11[C@H](C(O)=O)CCC%11)=O)CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)=O)CCC(N)=O)=O)=O)CCC%10)=O)CCC(N)=O)=O)C)=O)=O)CCC9)=O)CCC(N)=O)=O)C)=O)=O)CCC8)=O)CCC(N)=O)=O)C)=O)=O)CCC7)=O)CCC(N)=O)=O)C)=O)=O)CCC6)=O)CCC(N)=O)=O)C)=O)=O)CCC5)=O)CCC(N)=O)=O)C)=O)=O)CCC4)=O)CCC(N)=O)=O)C)=O)=O)CCC3)=O)CCC(N)=O)=O)C)=O)=O)CCC2)=O)CCC(N)=O)=O)C)=O)=O)=O)=O)=O)CCCNC(N)=N)=O)C(C)C)=O)CC(C)C)=O)CC%12=CNC%13=CC=CC=C%12%13)=O)C)=O)[C@H](CC)C)=O)CC%14=CC=CC=C%14)=O)CCC(O)=O)=O)CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)=O)C)=O)C)=O)CCC(N)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)CC(C)C)=O)CC%15=CC=C(O)C=C%15)=O)CO)=O)CO)=O)C(C)C)=O)CC(O)=O)=O)CO)=O)[C@@H](C)O)=O)CC%16=CC=CC=C%16)=O)[C@@H](C)O)=O)=O)CCC(O)=O)=O)C
Biological Activity: Zovaglutide (ZT002) is a long-acting, selective GLP-1 receptor agonist. Zovaglutide enhances albumin binding capacity via dual fatty acid chain modification. Zovaglutide exerts metabolic effects through central and peripheral GLP-1 pathways, thereby promoting satiety, reducing caloric intake and enhancing glucose-dependent insulin secretion, with no activity against GIP or glucagon receptors. Zovaglutide can be used in research on type 2 diabetes or obesity[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Zovaglutide | 99.25% | Zovaglutide (ZT002) is a long-acting, selective GLP-1 receptor agonist. Zovaglutide enhances albumin binding capacity via dual fatty acid chain modification. Zovaglutide exerts metabolic effects through central and peripheral GLP-1 pathways, thereby promoting satiety, reducing caloric intake and enhancing glucose-dependent insulin secretion, with no activity against GIP or glucagon receptors. Zovaglutide can be used in research on type 2 diabetes or obesity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
